+Search query
-Structure paper
Title | Discovery of a 2'-α-Fluoro-2'-β--(fluoromethyl) Purine Nucleotide Prodrug as a Potential Oral Anti-SARS-CoV-2 Agent. |
---|---|
Journal, issue, pages | J Med Chem, Vol. 68, Issue 2, Page 1994-2007, Year 2025 |
Publish date | Jan 23, 2025 |
![]() | Lan Liang / Yonggang Meng / Xiaoyu Chang / Ertong Li / Yucen Huang / Liming Yan / Zhiyong Lou / Youmei Peng / Bo Zhu / Wenquan Yu / Junbiao Chang / ![]() |
PubMed Abstract | A novel 2'-α-fluoro-2'-β--(fluoromethyl) purine nucleoside phosphoramidate prodrug has been designed and synthesized to treat SARS-CoV-2 infection. The SARS-CoV-2 central replication transcription ...A novel 2'-α-fluoro-2'-β--(fluoromethyl) purine nucleoside phosphoramidate prodrug has been designed and synthesized to treat SARS-CoV-2 infection. The SARS-CoV-2 central replication transcription complex (C-RTC, nsp12-nsp7-nsp8) catalyzed in vitro RNA synthesis was effectively inhibited by the corresponding bioactive nucleoside triphosphate (). The cryo-electron microscopy structure of the C-RTC: complex was also determined. Compound exhibited potent in vitro antiviral activity against the SARS-CoV-2 20SF107 strain (EC = 0.56 ± 0.06 μM) and the Omicron BA.5 variant (EC = 0.96 ± 0.23 μM) with low cytotoxicity. Furthermore, it was well tolerated in rats at doses of up to 2000 mg/kg, and a single oral dose of this prodrug at 40 mg/kg led to high levels of in the target organ lungs of rats with a long half-life. These findings support the further development of compound as an orally available antiviral agent for the treatment of SARS-CoV-2 infection. |
![]() | ![]() ![]() |
Methods | EM (single particle) |
Resolution | 2.9 Å |
Structure data | EMDB-62692, PDB-9l09: |
Chemicals | ![]() ChemComp-ZN: ![]() ChemComp-MG: ![]() ChemComp-HOH: |
Source |
|
![]() | VIRAL PROTEIN/RNA / SARS-CoV-2 C-RTC / VIRAL PROTEIN-RNA complex |